T. Rowe Price Associates, Inc. 13D and 13G filings for Global Blood Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-14 2:34 pm Sale |
2021-12-31 | 13G | Global Blood Therapeutics, Inc. GBT |
T. Rowe Price Associates, Inc. | 3,260,685 5.000% |
-802,438 (-19.75%) |
Filing |
| 2021-02-16 12:23 pm Sale |
2020-12-31 | 13G | Global Blood Therapeutics, Inc. GBT |
T. Rowe Price Associates, Inc. | 4,063,123 6.500% |
-1,593,062 (-28.16%) |
Filing |